INDIA MARKET LENS

Acutaas Chemicals Limited (ACUTAAS): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Acutaas Chemicals Limited, explained in plain English.

  • Acutaas Chemicals Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • ACUTAAS closed at ₹3,833.50 on 20 November 2026.
  • Over the past year the shares are up 121.3%, trading between ₹1,570.00 and ₹4,130.00.
  • Reported fundamentals show return on equity of 26.11%, a net margin of 27.58%, debt to equity of 0.79.
  • Our Pulse grade checklist scores it A (96/100) across momentum, growth, profitability and safety on fixed thresholds.
  • Annualised volatility over the past year is 45.83% with a maximum drawdown of -17.53% and a beta of 0.69 against NIFTY 50.
  • Recent coverage: Angel One flags breakout on Acutaas, Indus Towers and one more stock
  • Recent coverage: Nifty IT’s 18% rally may mark a durable leadership cycle; 35,000 next: LKP's Vatsal Bhuva

Other Pharma & Healthcare companies: Abbott India, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 20 Nov 2026. Market closed.

Acutaas Chemicals Limited (ACUTAAS)

₹3,991.3

▲ 48.4 (+1.23%)

Price & volume

ACUTAAS price chart, 1Y range. 252 points from 2025-11-20 to 2026-11-18. Opens at 1,732.4, closes at 3,991.3, ranging between 1,602.5 and 4,039.1.2,0003,0004,000Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 5/5
✓ Above 50-day avg✓ Above 200-day avgRSI 64.3 · healthyMACD positiveBollinger %B 69ADX 27.7 · strong trend

1M

+24.49%

3M

+17.69%

6M

+42.59%

1Y

+132.86%

Where it sits in its 52-week range

98%
₹1,602.5₹4,039.1

Below 52-week high

1.2%

149.1% above the low

Momentum read

Strong

5/5 checks passed

52-wk high

₹4,039.1

52-wk low

₹1,602.5

Market cap

₹32,677 Cr

P/E (trailing)

74.7

Dividend yield

—

ROE

26.11%

Profit margin

27.58%

Revenue growth

42.7%

Price / Book

17.59

Debt / Equity

0.79

EPS (TTM)

53.42

Book value

₹226.9

Beta

0.68

Pulse grade: A, 96 out of 100

Momentum

A
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✓Positive 3-month return

Growth

A
  • ✓Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

A
  • ✓Return on equity above Pharma & Healthcare median (14.56%)
  • ✓Return on equity above 12%
  • ✓Profit margin above Pharma & Healthcare median (13.82%)

Safety

A
  • ✓Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹437 crore · net profit ₹125 crore · margin 28.6%

4370Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,871.5+0.08%-6.48%
DRREDDY1,398.2+0.73%0.00%
CIPLA1,417+2.09%-7.46%
DIVISLAB11,049-0.91%-4.47%
APOLLOHOSP8,821+1.25%-2.73%
LUPIN1,971.9+1.12%-21.59%

ACUTAAS headlines

No ACUTAAS stories right now.

ACUTAAS filings & announcements

Reading the exchange…

ACUTAAS, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

46.72%

Sharpe ratio

1.89

Sortino ratio

3.11

Max drawdown

-17.53%

Daily VaR (95%)

-3.99%

CAGR (1Y)

131.16%

Return skew

0.41

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.